Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plixorafenib Alone or With Retifanlimab in BRAF-Altered Glioma
NCT06610682Phase 1Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of plixorafenib in glioma (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Detection rate of BRAF-V600E ctDNA in CSF and/or plasma at 4 weeks. Started Apr 2025; status: recruiting.
02
Drugs
plixorafenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06610682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610682.